FindTrial
Sign In

30mmHg) with mPAP at rest&lt

2 trials

Sponsors

Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School, Department of Respiratory Medicine, Nippon Medical School

Conditions

Patients with COPD or IIPs (WHO functional class II, III or IV), without hypoxia (PaO2 at rest&ltPatients with COPD or IPF (WHO functional class II, III or IV), without hypoxia (PaO2 at rest&lt

Unknown Phase

A study to evaluate the long-term effect of pulmonary hypertension on prognosis, activities of daily living (ADL), cardiac function and pulmonary function in patients with COPD and IPF, respectively, according to baseline severity of pulmonary hypertension and the efficacy and safety of the Tracleer (bosentan hydrate) tablet for prognosis, activities of daily living, cardiac function and pulmonary function in patients with COPD and IIPs, respectively, according to baseline severity of pulmonary hypertension.
RecruitingJPRN-UMIN000004749
Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical SchoolPatients with COPD or IPF (WHO functional class II, III or IV), without hypoxia (PaO2 at rest&lt
Start: 2011-01-01Target: 160Updated: 2026-06-29
A study to evaluate the long-term effect of Endothelin Receptor Antagonist(ERA) in patients with pulmonary hypertension related with COPD and Idiopathic interstitial pneumonia (IIPs), respectively.
RecruitingJPRN-UMIN000042159
Department of Respiratory Medicine, Nippon Medical SchoolPatients with COPD or IIPs (WHO functional class II, III or IV), without hypoxia (PaO2 at rest&lt
Start: 2020-10-05Target: 150Updated: 2026-06-29

Related Papers

Pulmonary vascular resistance is associated with two-year clinical outcomes in non-hypoxemic COPD with mild pulmonary hemodynamic abnormalities.
2026-05-15
Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention-prospective, single-center, randomized, parallel-group study.
2024-02-172 citations
Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study.
2017-12-1311 citations